Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 4.64 8.54% 0.37
FENC closed up 8.54 percent on Wednesday, November 20, 2024, on 1.96 times normal volume. It ran into resistance at its 50 day moving average.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Slingshot Bearish Bearish Swing Setup 8.54%
Bullish Engulfing Bullish 8.54%
Oversold Stochastic Weakness 8.54%
Doji - Bullish? Reversal 14.99%

   Recent Intraday Alerts

Alert Time
Rose Above 20 DMA about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Rose Above 10 DMA about 21 hours ago
1.5x Volume Pace about 21 hours ago
Up 5% about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fennec Pharmaceuticals Inc. Description

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Oncology Blastoma Sarcoma Hearing Brain Tumor Cancer Therapeutics Childhood Neuroblastoma Neoplasms Osteosarcoma Localized Tumors

Is FENC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.92
52 Week Low 3.96
Average Volume 97,288
200-Day Moving Average 7.08
50-Day Moving Average 4.67
20-Day Moving Average 4.44
10-Day Moving Average 4.30
Average True Range 0.32
RSI (14) 53.27
ADX 20.64
+DI 30.28
-DI 26.26
Chandelier Exit (Long, 3 ATRs) 4.09
Chandelier Exit (Short, 3 ATRs) 4.91
Upper Bollinger Bands 4.95
Lower Bollinger Band 3.94
Percent B (%b) 0.7
BandWidth 22.59
MACD Line -0.11
MACD Signal Line -0.12
MACD Histogram 0.0124
Fundamentals Value
Market Cap 123.93 Million
Num Shares 26.7 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -6.19
Price-to-Sales 20.81
Price-to-Book 84.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.51
Resistance 3 (R3) 5.46 5.13 5.37
Resistance 2 (R2) 5.13 4.91 5.15 5.32
Resistance 1 (R1) 4.88 4.77 5.01 4.93 5.27
Pivot Point 4.55 4.55 4.61 4.57 4.55
Support 1 (S1) 4.30 4.33 4.43 4.35 4.01
Support 2 (S2) 3.97 4.19 3.99 3.96
Support 3 (S3) 3.72 3.97 3.92
Support 4 (S4) 3.77